M2D2 at UMass Lowell
Mary Ann PicardAssociate Director
Madison County Economic Development Authority - Mississippi Bio-Medical Business Collaboratory
The Madison County Economic Development Authority, or MCEDA as we are known locally, offers a broad array of economic development, business development, and corporate site location assistance services to new and expanding businesses and industry.
MCEDA owns the newly created Mississippi Bio-Medical Business Collaboratory. A 60,000 square foot office and educational services facility for bio-medical and medical related companies. We are seeking new tenants for the facility. Current tenants include: TeleHealthOne (telemedicine provider), Xerox, Mississippi Association of Nurse Practitioners, and the Global Training Institute (a brand new state-of-the art Surgical and Medical Simulation Center).
Mr Tim CourseyExecutive Director
Ms Danielle WinninghamBusiness Development Manager
Masonic Medical Research Laboratory
Masonic Medical Research Laboratory is a not-for-profit institute dedicated to improving the health and quality of life for all. The Laboratory's primary mission is to conduct high quality basic and clinical research aimed at generating knowledge and information necessary for development of medical cures and treatments of tomorrow. The Laboratory is also committed to providing education and training to basic scientists, clinical researchers and students who will perpetuate and extend the fight against disease.Specialties
The Laboratory's primary focus is on basic medical research in the fields of Experimental Cardiology, Cardiac Electrophysiology, Molecular Biology and Molecular Genetics.
Dr John Story,JrDirector of Administration
Dr Hector Barajas-MartinezClinical Director of Molecular Genetics
Dr Matthew BetzenhauserActing Director of Research
Mass Innovation Labs
ass Innovation Labs embodies an ecosystem of innovators in its 124,000 square foot first-class chemistry and biology space in the heart of Kendall Square. We provide comprehensive solutions for growing companies, including animal facilities, co-located CRO services and operational needs. Our goal is to reduce the time for teams to overcome hurdles on their way to a milestone. Our space offers a collaborative ecosystem that allows a company to run as a lean organization and focus on the science with expert drug development partners down the hall.
At Milabs, our full service offerings allow you to innovate like a start up while commercializing like a pharma.
Call us to schedule a visit!
R&D ACCELERATION IN A COLLABORATIVE ECOSYSTEM, TOP QUALITY RESEARCH SPACES AND RESOURCES, FACILITATE BIOTECH OPPORTUNITIES, IN-HOUSE MANAGEMENT SERVICES AND EXPERTISE
Massat Consulting Group
Certified Public Accountants
“We are above all a human size company built by men and women used to make decisions on a daily basis without having to refer for authorization to a heavy hierarchy” (Serge J. Massat, 2001).
At Massat Consulting Group we focus on the International client with subsidiaries abroad. We serve as a link and interface between the parent company and its subsidiaries.
Our Partners and Managers are Certified Public Accountant (CPA) in the USA but also “Expert Comptables” in France , “Contadores Publicos” in Mexico and Chartered Accountant in the United Kingdom.
Our team speak English, French and Spanish.
Mr Andrew MassatPartner
MEBIAS holds a game-changing platform to discover next generation, pathway-selective GPCR drugs devoid of on-target side effects once thought to be unavoidable.
• Fully validated in vitro and ex vivo assay suite correlating ligand-induced dynamic conformation of GPCR to pathway-specific signaling
• Differentiated mu-opioid receptor pre-development candidates for the treatment of pain, plus backup molecules
MEBIAS seeks capital to establish a NewCo:
• To co-develop our mu-opioid drug candidate
• To fund lead discovery of additional targets
Shariff Bayoumy – Unique expertise in GPCR expression and purification; former head of Janssen gene‑to‑protein team on soluble and membrane proteins
Lawrence Kuo – Former head, Structural Biology (Janssen); former head, Enzymology and Structural Biology (Merck); core member of project teams for Crixivan™ and Stocrin™
Brett A. Tounge – Extensive expertise in designing drug like small molecules from hit discovery through NME declaration; former head of Janssen NMR team
G-protein coupled receptor (GPCR) therapeutics exhibit significant on-target adverse effects that can be alleviated by developing pathway-selective/biased drugs. The clinical benefit to dial pathway selectivity into future GPCR drugs has been clearly established, but current discovery approaches in the pharma/biotech industry are inadequate to speedily design and develop biased drugs.
With the downsizing of internal R&D in the pharma industry, there is a dire need for new discovery platforms and assets to help fill early pipelines. GPCR therapeutics comprise ~30% of current prescribed drugs with a global market of >USD100 billion and a projected growth of 20% by 2018.
Our immediate targeted customers will be pharma and biotech R&D. Our intention is to co-develop GPCR pathway-selective drugs to treat CNS, Metabolic, and Inflammatory related disorders. The pathway-selective GPCR landscape is wide open.
The first round of funding from investors will be used to form a NewCo with the specific goal to discover and progress pre-development candidates for pathway-selective GPCR indications. In hand we hold differentiated mu-opioid receptor pre-development candidates for the treatment of pain. Revenues from the sale or partnering of our pre-clinical assets will fund new R&D efforts.
Additional players in the GPCR pathway selectivity space are highly desirable to help advance clinical need in numerous disease areas. Given our experience and access to two key technologies – native GPCR purification and protein nuclear magnetic resonance – our approach offers unique advantages lacking in current methodologies (that employ only cell-based assays). We have demonstrated our competitive advantage by successfully delivering a series of mu‑opioid receptor compounds among which is an NME-stage compound.
Dr LAWRENCE KUOSenior Director
Dr Brett ToungeAssociate Director
Mr Shariff Bayoumy
Your innovative solution
Our technology helps automate/standardize image interpretation ; it also enables quantification of standard imaging criteria and advanced imaging biomarkers, to provide early proof of treatment response. Our Lesion Management Solutions (LMS) platform is a proprietary suite of software modules for automated/semi-automated detection, quantitative measurement and follow-up of tumors.
MEDIAN's technology solves frequently observed issues in image interpretation such as intra- and inter-reader variability of measurement or lack of standardization of reading/interpretation processes. Both variability and insufficient level of standardization lead to a decrease of imaging data reliability, which can, for instance impact the statistical power of data in clinical trials.
Oncology drug development -clinical trials (phases I to phases III) / Novel biomarkers development in oncology and other therapeutic areas / Imaging based cancer screening programs
Quantitative and standardized data analysis supported by cutting edge, FDA approved, technology / Expertise in advanced imaging biomarkers for more accurate evaluation of drug efficacy / Real time, streamlined image workflow for clinical trials